Philips
Manufactures sleep therapy and respiratory devices
Customer Success Executive - NYC
+ Annual incentive bonus + Sales commission + Long-term incentives
More locations: Brooklyn, NY, USA | White Plains, NY, USA
Must reside in or within commuting distance of New York City; expect 50–75% local travel.
About the job
- At least 5 years of experience in strategic Customer Relationship Management, Customer Success, Clinical Transformation, or a similar area; hospital healthcare or medical device industry experience is required.
- Strong executive influence, a strategic mindset, and cross-functional leadership internally and externally.
- Knowledge of Salesforce to evaluate, manage, and present key performance indicators and success plans to leadership.
- A deep understanding of hospital networks and workflows.
- A bachelor's or master's degree or equivalent, or at least 9 years of related experience.
- Ability to meet the minimum physical, cognitive, and environmental job requirements, with or without accommodation.
- Proficiency in developing presentations and reports, with strong written and verbal communication.
- Oversee the full lifecycle of strategy, execution, adoption, and value delivery for long-term strategic partnerships within the Hospital Patient Monitoring ecosystem.
- Drive clinical, operational, and financial improvements by working with clinical, operational, technical, and executive stakeholders; ensure customers fully adopt and optimize monitoring solutions, including bedside and transport monitors, central stations, mobility and notification tools, clinical decision support applications, and interoperability components.
- Develop and manage a unified, data-driven customer success and outcomes roadmap across strategic partnerships and traditional Hospital Patient Monitoring service models, while expanding Philips’ presence within accounts.
- Collaborate with Sales, Services, and Solutions & Delivery teams to ensure seamless project delivery; partner with Sales to secure renewals, grow existing agreements, transition customers to higher-value offerings, add addendums, and expand adoption of the Philips portfolio.
- Serve as a trusted advisor by connecting customer objectives to Philips’ monitoring and enterprise portfolio, including diagnostic cardiology, software solutions, interoperability capabilities, and emerging innovations.
- Hospital patient monitoring knowledge is highly preferred.
- A current Gainsight certification is a plus.
About the company
Philips Respironics designs sleep and respiratory care devices, including CPAP and BiPAP machines, ventilators, and oxygen concentrators, plus related systems. These devices deliver regulated air pressure, support or assist breathing, and provide concentrated oxygen, often paired with software and data tools for monitoring. The division differentiates itself through its long history within Philips and its integrated ecosystem that connects devices with analytics and clinical support across hospital, clinic, and home settings. Its goal is to improve quality of life and clinical outcomes for people with sleep and respiratory conditions by offering reliable devices, patient support, and data-driven care.
Company Size
N/A
Company Stage
Acquired
Total Funding
$164.7M
Headquarters
Murrysville, Pennsylvania
Founded
1891
Simplify's Take
What believers are saying
- More than 99% of registered CPAP and BiPAP recalls were remediated globally by December 2025.
- Philips reported Q1 2026 connected care growth and reiterated full-year guidance in May.
- Respironics-related charges fell to EUR 209 million in 2025 after major settlements finalized.
What critics are saying
- FDA consent decree still bars new U.S. CPAP and BiPAP sales in 2026.
- Repeated FDA noncompliance can keep Philips Respironics locked out of the U.S. market indefinitely.
- The 2021 recall remains active; ventilator remediation and lawsuits keep liability and scrutiny alive.
What makes Philips unique
- Philips Respironics services recalled U.S. devices and sells parts under the 2024 consent decree.
- Outside the U.S., Philips Respironics still sells sleep and respiratory devices in 2026.
- Its 15-million-device installed base gives it unmatched service reach and replacement leverage.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.